Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024
PeerView
290 views
7 slides
Jul 01, 2024
Slide 1 of 7
1
2
3
4
5
6
7
About This Presentation
Chair and Presenter, Stephen V. Liu, MD, Benjamin Levy, MD, Jessica J. Lin, MD, and Prof. Solange Peters, MD, PhD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/NCPD/AAPA/IPCE activity titled “Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 202...
Slide Content
NSCLC Treatment Algorithm
1
Full abbreviations, accreditation, and disclosure information available at PeerView.com/TFK40
Stage and workup based on stage
• cT1abc, N0: PFT, bronch, mediastinal staging, PET
• cT2a-4, N0-3, M0-1: PFT, bronch, mediastinal staging, PET, brain MRI, and biomarker/mutation testing
Surgical candidate?
Lobectomy
(preferred)
or
segmentectomy/
wedge resection
(in select cases)
SBRT
or
conventionally
fractionated RT
Surgical resection
Test for PD-L1 status,
EGFR mutations,
and ALK rearrangements
Surgical resection
T1
N0
M0
Operable disease
Yes
Yes
No
No
Multidisciplinary discussion for
neoadjuvant candidacy
T1–2, N1–2, M0
T3–4, N0–1, M0
Neoadjuvant
chemoimmunotherapy
Neoadjuvant portion of
perioperative immunotherapy
Nivolumab + platinum-based
chemotherapy x 3 cycles
CheckMate -816: Nivo + chemo vs
chemo (see FDA approval)
mEFS: 31.6 vs 20.8 mo (HR, 0.63)
Pembrolizumab + platinum-containing chemotherapy x 4
cycles as neoadjuvant
KEYNOTE-671: Pembro + chemo vs placebo + chemo
(neoadjuvant) / pembro vs placebo (adjuvant)
(see FDA approval)
mOS: not reached vs 52.4 mo; mEFS: not reached vs 17 mo
Adjuvant chemotherapy
Platinum-based chemotherapy
LACE Meta-analysis: 5-y OS improvement of 5.4% vs no chemo
Atezolizumab x 16 cycles
Stage II-IIIA, PD-L1 ≥1% (see FDA approval)
Atezolizumab x 16 cycles
IMpower010: Atezo vs BSC
mDFS: NR vs 35.3 mo (HR, 0.66)
Pembrolizumab x 1 y
Stage IB (T2a ≥4 cm), II, or IIIA, regardless
of PD-L1 expression (see FDA approval)
Pembrolizumab x 1 y
PEARLS/KEYNOTE-091: Pembro vs placebo
mDFS: 53.6 vs 42.0 mo (HR, 0.76)
Adjuvant EGFR-targeted therapy
Osimertinib x 3 y
ADAURA: Osimertinib vs placebo
2-y DFS (stage II-IIIA): 90% vs 44% (HR, 0.17)
NSCLC treatment algorithm
Stage IB-IIIA
(resectable)Stage IA
Surgical resection
Adjuvant portion of perioperative immunotherapy
Pembrolizumab, up to 13 cycles
KEYNOTE-671: Pembro + chemo vs placebo + chemo
(neoadjuvant) / pembro vs placebo (adjuvant)
(see FDA approval)
mOS: not reached vs 52.4 mo; mEFS: not reached vs 17 mo
Yes
Adjuvant ALK-targeted therapy
Alectinib x 24 mo
ALINA: Alectinib vs chemo
mDFS: NR vs 41.3 mo
Adjuvant immunotherapy (stage II-IIIA)
ALK rearrangement
EGFR ex19del/
ex21 L858R
EGFR ex19del/
ex21 L858R
1
Full abbreviations, accreditation, and disclosure information available at PeerView.com/TFK40
Stage and workup based on stage
• cT1abc, N0: PFT, bronch, mediastinal staging, PET
• cT2a-4, N0-3, M0-1: PFT, bronch, mediastinal staging, PET, brain MRI, and biomarker/mutation testing
Surgical candidate?
Lobectomy
(preferred)
or
segmentectomy/
wedge resection
(in select cases)
SBRT
or
conventionally
fractionated RT
Surgical resection
Test for PD-L1 status,
EGFR mutations,
and ALK rearrangements
Surgical resection
T1
N0
M0
Operable disease
Yes
Yes
No
No
Multidisciplinary discussion for
neoadjuvant candidacy
T1–2, N1–2, M0
T3–4, N0–1, M0
Neoadjuvant
chemoimmunotherapy
Neoadjuvant portion of
perioperative immunotherapy
Nivolumab + platinum-based
chemotherapy x 3 cycles
CheckMate -816: Nivo + chemo vs
chemo (see FDA approval)
mEFS: 31.6 vs 20.8 mo (HR, 0.63)
Pembrolizumab + platinum-containing chemotherapy x 4
cycles as neoadjuvant
KEYNOTE-671: Pembro + chemo vs placebo + chemo
(neoadjuvant) / pembro vs placebo (adjuvant)
(see FDA approval)
mOS: not reached vs 52.4 mo; mEFS: not reached vs 17 mo
Adjuvant chemotherapy
Platinum-based chemotherapy
LACE Meta-analysis: 5-y OS improvement of 5.4% vs no chemo
Atezolizumab x 16 cycles
Stage II-IIIA, PD-L1 ≥1% (see FDA approval)
Atezolizumab x 16 cycles
IMpower010: Atezo vs BSC
mDFS: NR vs 35.3 mo (HR, 0.66)
Pembrolizumab x 1 y
Stage IB (T2a ≥4 cm), II, or IIIA, regardless
of PD-L1 expression (see FDA approval)
Pembrolizumab x 1 y
PEARLS/KEYNOTE-091: Pembro vs placebo
mDFS: 53.6 vs 42.0 mo (HR, 0.76)
Adjuvant EGFR-targeted therapy
Osimertinib x 3 y
ADAURA: Osimertinib vs placebo
2-y DFS (stage II-IIIA): 90% vs 44% (HR, 0.17)
NSCLC treatment algorithm
Stage IB-IIIA
(resectable)Stage IA
Surgical resection
Adjuvant portion of perioperative immunotherapy
Pembrolizumab, up to 13 cycles
KEYNOTE-671: Pembro + chemo vs placebo + chemo
(neoadjuvant) / pembro vs placebo (adjuvant)
(see FDA approval)
mOS: not reached vs 52.4 mo; mEFS: not reached vs 17 mo
Yes
Adjuvant ALK-targeted therapy
Alectinib x 24 mo
ALINA: Alectinib vs chemo
mDFS: NR vs 41.3 mo
Adjuvant immunotherapy (stage II-IIIA)
ALK rearrangement
EGFR ex19del/
ex21 L858R
EGFR ex19del/
ex21 L858R
Stage IIIA (unresectable) or IIIB/C
Definitive chemoradiation → durvalumab
Concurrent platinum-based chemotherapy and radiation with
consolidation durvalumab
PACIFIC: Durvalumab vs placebo
mPFS: 16.8 vs 5.6 mo (HR, 0.52)
BRAF V600E
Dabrafenib + trametinib
a
BRF113928: Dabrafenib + trametinib single arm
ORR: 64% (95% CI, 46-79)
Encorafenib + binimetinib
a
PHAROS: Encorafenib + binimetinib single arm (see FDA approval)
Treatment-naïve patients, ORR: 75% (95% CI, 62-85); mDOR: NE (95% CI, 23.1-NE)
Previously treated patients, ORR: 46% (95% CI, 30-63); mDOR: 16.7 mo (95% CI, 7.4-NE)
Vemurafenib
AcSé: Vemurafenib single arm
ORR: 45%; mPFS: 5.2 mo; OS: 10 mo
2L: KRAS G12C
Sotorasib
CodeBreaK100: Sotorasib single arm
ORR: 37.1% (95% CI, 29-46); mPFS: 6.8 mo
Adagrasib
K RY STA L-1: Adagrasib single arm (see FDA approval)
ORR: 43% (95% CI, 34-53); mDOR: 8.5 mo
ALK
Alectinib
a
ALEX: Alectinib vs crizotinib
1-y PFS: 68.4% vs 48.7% (HR, 0.47)
Brigatinib
a
ALTA-1L: Brigatinib vs crizotinib
mPFS: 24 vs 11.1 mo (HR, 0.48)
Lorlatinib
a
CROWN: Lorlatinib vs crizotinib
mPFS: NR vs 9.3 mo (HR, 0.28); 1-y PFS: 78% vs 39%
Ceritinib
ASCEND-4: Ceritinib vs chemo
mPFS: 16.6 vs 8.1 mo (HR, 0.55)
Crizotinib
PROFILE 1007: Crizotinib vs chemo
mPFS: 7.7 vs 3 mo (HR, 0.49)
NTRK
Larotrectenib
a
NCT02122913/SCOUT/NAVIGATE : Larotrectenib single arm (see FDA approval)
ORR: 75% according to independent review and 80% according to investigator assessment
Entrectinib
a
ALKA/STARTRK: Entrectinib single arm (see FDA approval)
ORR: 70% (NSCLC)
RET
EGFR S768I, L861Q, and/or G719X
Selpercatinib
a
LIBRETTO-001: Selpercatinib single arm (see FDA approval)
ORR: 64%; mDOR: 17.5 mo
Pralsetinib
a
ARROW: Pralsetinib single arm (see FDA approval)
Treatment-naïve patients, ORR: 78% (95% CI, 68-85); mDOR: 13.4 mo (95% CI, 9.4-23.1)
Previously treated patients, ORR: 63% (95% CI, 54-71); mDOR: 38.8 mo (95% CI, 14.8-NE)
Cabozantinib
NCT01639508: Cabozantinib single arm
ORR: 28%
Osimertinib
a
FLAURA: Osimertinib vs erlotinib/gefitinib
mPFS: 18.9 vs 10.2 mo (HR, 0.46)
Erlotinib
EU RTAC: Erlotinib vs chemo
mPFS: 9.7 vs 5.2 mo (HR, 0.37)
Afatinib
a
LUX-Lung 3: Afatinib vs cis/pemetrexed
mPFS: 13.6 vs 6.9 mo (HR, 0.47)
Gefitinib
IFUM: Gefitinib single arm
mPFS: 9.7 mo
Dacomitinib
ARCHER 1050: Dacomitinib vs gefitinib
mOS: 34.1 vs 27 mo (HR, 0.75)
Amivantamab + carboplatin + pemetrexed (nonsquamous)
MARIPOSA-2: Amivantamab + chemo ± lazertinib vs chemo
mPFS: 6.3, 8.3 vs 4.2 mo (HR, 0.48, 0.44); ORR: 64%, 63% vs 36% (P < .001 for both)
EGFR (ex20)
Amivantamab
CHRYSALIS: Amivantamab single arm
CBR: 74% (95%CI, 63-83); mPFS: 8.3 mo
Amivantamab + carboplatin + pemetrexed (nonsquamous)
a
PAPILLON: Amivantamab + chemo vs chemo
mPFS: 11.4 vs 6.7 mo (HR, 0.4); ORR: 73% vs 47%
ROS1
Crizotinib
a
PROFILE 1001: Crizotinib single arm
ORR: 72% (95% CI, 58-84)
Entrectinib
a
ALK A & STARTRK: Entrectinib single arm
ORR: 67.1%; mPFS: 19 mo
Ceritinib
YONSEI: Ceritinib single arm
ORR: 67% (95% CI, 48-81)
Repotrectinib
a
TRIDENT-1: Repotrectinib single arm (see FDA approval)
ROS1 TKI-naïve patients, ORR: 79% (95% CI, 68-88); mDOR: 34.1 mo (95% CI, 25.6-NE)
Prior ROS1 inhibitor, ORR: 38% (95% CI, 25-52); mDOR: 14.8 mo (95% CI, 7.6-NE)
Lorlatinib
NCT01970865: Lorlatinib single arm
ROS TKI-naïve patients, ORR: 62%; Crizotinib pre-treated patients, ORR: 35%
EGFR (ex19 del or L858R)
Osimertinib
a
FLAURA: Osimertinib vs erlotinib/gefitinib
mPFS: 18.9 vs 10.2 mo (HR, 0.46)
Osimertinib + pemetrexed + cisplatin/carboplatin
FLAURA2: Osimertinib + chemo vs osimertinib (see FDA approval)
mPFS: 25.5 vs 16.7 mo (HR, 0.62)
Erlotinib
EU RTAC: Erlotinib vs chemo
mPFS: 9.7 vs 5.2 mo (HR, 0.37)
Afatinib
LUX-Lung 3: Afatinib vs cis/pemetrexed
mPFS: 13.6 vs 6.9 mo (HR, 0.47)
Gefitinib
IFUM: Gefitinib single arm
mPFS: 9.7 mo
Dacomitinib
ARCHER 1050: Dacomitinib vs gefitinib
mOS: 34.1 vs 27 mo (HR, 0.75)
Erlotinib + ramucirumab
R E L AY: Erlotinib + ramucirumab vs erlotinib
mPFS: 19.4 vs 12.4 mo (HR, 0.59)
Erlotinib + bevacizumab (nonsquamous)
ARTEMIS-CTONG1509 : Erlotinib + bevacizumab vs erlotinib
mPFS: 17.9 vs 11.2 mo (HR, 0.55)
Amivantamab + carboplatin + pemetrexed (nonsquamous)
MARIPOSA-2: Amivantamab + chemo ± lazertinib vs chemo
mPFS: 6.3, 8.3 vs 4.2 mo (HR, 0.48, 0.44); ORR: 64%, 63% vs 36% (P < .001 for both)
MET (exon 14)
Capmatinib
a
GEOMETRY mono-1: Capmatinib single arm (see FDA approval)
mPFS: 12.4 mo; treatment-naïve patients, ORR: 68% (95% CI, 55-80); DOR: 16.6 mo
Previously treated patients, ORR: 44% (95% CI, 34-54); DOR: 9.7 mo
Tepotinib
a
VISION: Tepotinib single arm
mPFS: 8.5-11 mo
Crizotinib
PROFILE 1001: Crizotinib single arm
ORR: 32%
2L: HER2
Trastuzumab deruxtecan
a
DESTINY-Lung02: T-DXd 5.4 mg/kg vs 6.4 mg/kg (see FDA approval)
ORR: 58% (98% CI, 43-71); mDOR: 8.7 mo (95% CI, 7.1-NE)
Trastuzumab emtansine
NCT02675829: Trastuzumab emtansine single arm
ORR: 44%
T1-2, N2–3, M0
T3, N1–3, M0
T4, N0–3, M0
Tx
Nx
M1
Actionable mutation detected
Mutation (broad NGS if possible) and PD-L1 testing
NSCLC treatment algorithm
Stage and workup based on stage
• cT1abc, N0: PFT, bronch, mediastinal staging, PET
• cT2a- 4, N0-3, M0-1: PFT, bronch, mediastinal staging, PET, brain MRI, and biomarker/mutation testing
Please see the next page for recommendations if no actionable mutation is detected
Stage IV
• EGFR
• ALK
• ROS1
• BRAF V600E
• RET
• MET (ex14)
• HER2
• NTRK1/2/3
• KRAS G12C
NSCLC Treatment Algorithm
1
Full abbreviations, accreditation, and disclosure information available at PeerView.com/TFK40
Definitive chemoradiation → durvalumab
Concurrent platinum-based chemotherapy and radiation with
consolidation durvalumab
PACIFIC: Durvalumab vs placebo
mPFS: 16.8 vs 5.6 mo (HR, 0.52)
BRAF V600E
Dabrafenib + trametinib
a
BRF113928: Dabrafenib + trametinib single arm
ORR: 64% (95% CI, 46-79)
Encorafenib + binimetinib
a
PHAROS: Encorafenib + binimetinib single arm (see FDA approval)
Treatment-naïve patients, ORR: 75% (95% CI, 62-85); mDOR: NE (95% CI, 23.1-NE)
Previously treated patients, ORR: 46% (95% CI, 30-63); mDOR: 16.7 mo (95% CI, 7.4-NE)
Vemurafenib
AcSé: Vemurafenib single arm
ORR: 45%; mPFS: 5.2 mo; OS: 10 mo
2L: KRAS G12C
Sotorasib
CodeBreaK100: Sotorasib single arm
ORR: 37.1% (95% CI, 29-46); mPFS: 6.8 mo
Adagrasib
K RY STA L-1: Adagrasib single arm (see FDA approval)
ORR: 43% (95% CI, 34-53); mDOR: 8.5 mo
ALK
Alectinib
a
ALEX: Alectinib vs crizotinib
1-y PFS: 68.4% vs 48.7% (HR, 0.47)
Brigatinib
a
ALTA-1L: Brigatinib vs crizotinib
mPFS: 24 vs 11.1 mo (HR, 0.48)
Lorlatinib
a
CROWN: Lorlatinib vs crizotinib
mPFS: NR vs 9.3 mo (HR, 0.28); 1-y PFS: 78% vs 39%
Ceritinib
ASCEND-4: Ceritinib vs chemo
mPFS: 16.6 vs 8.1 mo (HR, 0.55)
Crizotinib
PROFILE 1007: Crizotinib vs chemo
mPFS: 7.7 vs 3 mo (HR, 0.49)
NTRK
Larotrectenib
a
NCT02122913/SCOUT/NAVIGATE : Larotrectenib single arm (see FDA approval)
ORR: 75% according to independent review and 80% according to investigator assessment
Entrectinib
a
ALKA/STARTRK: Entrectinib single arm (see FDA approval)
ORR: 70% (NSCLC)
RET
EGFR S768I, L861Q, and/or G719X
Selpercatinib
a
LIBRETTO-001: Selpercatinib single arm (see FDA approval)
ORR: 64%; mDOR: 17.5 mo
Pralsetinib
a
ARROW: Pralsetinib single arm (see FDA approval)
Treatment-naïve patients, ORR: 78% (95% CI, 68-85); mDOR: 13.4 mo (95% CI, 9.4-23.1)
Previously treated patients, ORR: 63% (95% CI, 54-71); mDOR: 38.8 mo (95% CI, 14.8-NE)
Cabozantinib
NCT01639508: Cabozantinib single arm
ORR: 28%
Osimertinib
a
FLAURA: Osimertinib vs erlotinib/gefitinib
mPFS: 18.9 vs 10.2 mo (HR, 0.46)
Erlotinib
EU RTAC: Erlotinib vs chemo
mPFS: 9.7 vs 5.2 mo (HR, 0.37)
Afatinib
a
LUX-Lung 3: Afatinib vs cis/pemetrexed
mPFS: 13.6 vs 6.9 mo (HR, 0.47)
Gefitinib
IFUM: Gefitinib single arm
mPFS: 9.7 mo
Dacomitinib
ARCHER 1050: Dacomitinib vs gefitinib
mOS: 34.1 vs 27 mo (HR, 0.75)
Amivantamab + carboplatin + pemetrexed (nonsquamous)
MARIPOSA-2: Amivantamab + chemo ± lazertinib vs chemo
mPFS: 6.3, 8.3 vs 4.2 mo (HR, 0.48, 0.44); ORR: 64%, 63% vs 36% (P < .001 for both)
EGFR (ex20)
Amivantamab
CHRYSALIS: Amivantamab single arm
CBR: 74% (95%CI, 63-83); mPFS: 8.3 mo
Amivantamab + carboplatin + pemetrexed (nonsquamous)
a
PAPILLON: Amivantamab + chemo vs chemo
mPFS: 11.4 vs 6.7 mo (HR, 0.4); ORR: 73% vs 47%
ROS1
Crizotinib
a
PROFILE 1001: Crizotinib single arm
ORR: 72% (95% CI, 58-84)
Entrectinib
a
ALK A & STARTRK: Entrectinib single arm
ORR: 67.1%; mPFS: 19 mo
Ceritinib
YONSEI: Ceritinib single arm
ORR: 67% (95% CI, 48-81)
Repotrectinib
a
TRIDENT-1: Repotrectinib single arm (see FDA approval)
ROS1 TKI-naïve patients, ORR: 79% (95% CI, 68-88); mDOR: 34.1 mo (95% CI, 25.6-NE)
Prior ROS1 inhibitor, ORR: 38% (95% CI, 25-52); mDOR: 14.8 mo (95% CI, 7.6-NE)
Lorlatinib
NCT01970865: Lorlatinib single arm
ROS TKI-naïve patients, ORR: 62%; Crizotinib pre-treated patients, ORR: 35%
EGFR (ex19 del or L858R)
Osimertinib
a
FLAURA: Osimertinib vs erlotinib/gefitinib
mPFS: 18.9 vs 10.2 mo (HR, 0.46)
Osimertinib + pemetrexed + cisplatin/carboplatin
FLAURA2: Osimertinib + chemo vs osimertinib (see FDA approval)
mPFS: 25.5 vs 16.7 mo (HR, 0.62)
Erlotinib
EU RTAC: Erlotinib vs chemo
mPFS: 9.7 vs 5.2 mo (HR, 0.37)
Afatinib
LUX-Lung 3: Afatinib vs cis/pemetrexed
mPFS: 13.6 vs 6.9 mo (HR, 0.47)
Gefitinib
IFUM: Gefitinib single arm
mPFS: 9.7 mo
Dacomitinib
ARCHER 1050: Dacomitinib vs gefitinib
mOS: 34.1 vs 27 mo (HR, 0.75)
Erlotinib + ramucirumab
R E L AY: Erlotinib + ramucirumab vs erlotinib
mPFS: 19.4 vs 12.4 mo (HR, 0.59)
Erlotinib + bevacizumab (nonsquamous)
ARTEMIS-CTONG1509 : Erlotinib + bevacizumab vs erlotinib
mPFS: 17.9 vs 11.2 mo (HR, 0.55)
Amivantamab + carboplatin + pemetrexed (nonsquamous)
MARIPOSA-2: Amivantamab + chemo ± lazertinib vs chemo
mPFS: 6.3, 8.3 vs 4.2 mo (HR, 0.48, 0.44); ORR: 64%, 63% vs 36% (P < .001 for both)
MET (exon 14)
Capmatinib
a
GEOMETRY mono-1: Capmatinib single arm (see FDA approval)
mPFS: 12.4 mo; treatment-naïve patients, ORR: 68% (95% CI, 55-80); DOR: 16.6 mo
Previously treated patients, ORR: 44% (95% CI, 34-54); DOR: 9.7 mo
Tepotinib
a
VISION: Tepotinib single arm
mPFS: 8.5-11 mo
Crizotinib
PROFILE 1001: Crizotinib single arm
ORR: 32%
2L: HER2
Trastuzumab deruxtecan
a
DESTINY-Lung02: T-DXd 5.4 mg/kg vs 6.4 mg/kg (see FDA approval)
ORR: 58% (98% CI, 43-71); mDOR: 8.7 mo (95% CI, 7.1-NE)
Trastuzumab emtansine
NCT02675829: Trastuzumab emtansine single arm
ORR: 44%
T1-2, N2–3, M0
T3, N1–3, M0
T4, N0–3, M0
Tx
Nx
M1
Actionable mutation detected
Mutation (broad NGS if possible) and PD-L1 testing
NSCLC treatment algorithm
Stage and workup based on stage
• cT1abc, N0: PFT, bronch, mediastinal staging, PET
• cT2a- 4, N0-3, M0-1: PFT, bronch, mediastinal staging, PET, brain MRI, and biomarker/mutation testing
Please see the next page for recommendations if no actionable mutation is detected
Stage IV
• EGFR
• ALK
• ROS1
• BRAF V600E
• RET
• MET (ex14)
• HER2
• NTRK1/2/3
• KRAS G12C
NSCLC Treatment Algorithm
1
Full abbreviations, accreditation, and disclosure information available at PeerView.com/TFK40
a
Denotes NCCN-preferred regimens.
b
For patients who have no contraindications to PD-1 or PD-L1 inhibitors and who have a PS 0-1.
1. Adapted from an algorithm created by Aakash Desai, MBBS, MPH, and Matthew Ho, MD, PhD, with recent updates from NCCN Guidelines Version 5, 2024. Used with permission from the authors.
PD- L1 <1%
b
IMMUNOTHERAPY + CHEMOTHERAPY
SQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin + paclitaxel/nab-paclitaxel)
KEYNOTE-407: Pembro + chemo vs chemo
mPFS: 6.4 vs 4.8 mo (HR, 0.56); mOS: 15.9 vs 11.3 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(paclitaxel + carboplatin/cisplatin)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
NONSQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
KEYNOTE-189: Pembro + chemo vs chemo
mPFS: 8.8 vs 4.9 mo (HR, 0.52); 12-mo OS: 69% vs 49% (HR, 0.49)
• Atezolizumab + chemotherapy (carboplatin + paclitaxel + bevacizumab)
IMpower150: Atezo + chemo vs chemo
mPFS: 8.3 vs 6.8 mo (HR, 0.62)
• Atezolizumab + chemotherapy (carboplatin + nab-paclitaxel)
IMpower130: Atezo + chemo vs chemo
mOS: 18.6 vs 13.9 mo (HR, 0.79); mPFS: 7.0 vs 5.5 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
DUAL IMMUNOTHERAPY + CHEMOTHERAPY
SQUAMOUS:
• Nivolumab + ipilimumab + chemotherapy (paclitaxel/carboplatin)
CheckMate -9LA: Nivo/ipi + chemo vs chemo
mOS: 14.1 vs 10.7 mo
• Durvalumab + tremelimumab + chemotherapy (carboplatin + nab-paclitaxel)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
• Durvalumab + tremelimumab + chemotherapy (gemcitabine + carboplatin/cisplatin)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
NONSQUAMOUS:
• Nivolumab + ipilimumab + chemotherapy (paclitaxel/carboplatin)
CheckMate -9LA: Nivo/ipi + chemo vs chemo
mOS: 14.1 vs 10.7 mo
• Durvalumab + tremelimumab + chemotherapy (carboplatin + nab - paclitaxel)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
• Durvalumab + tremelimumab + chemotherapy (pemetrexed + carboplatin/cisplatin)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
DUAL IMMUNOTHERAPY
Nivolumab + ipilimumab
CheckMate -227: Nivo/ipi vs chemo
mOS: 17.1 vs 14.9 mo
DUAL IMMUNOTHERAPY
Nivolumab + ipilimumab
CheckMate -227: Nivo/ipi vs chemo
mOS: 17.1 vs 14.9 mo
DUAL IMMUNOTHERAPY + CHEMOTHERAPY
Nivolumab + ipilimumab + chemotherapy (pemetrexed + carboplatin/cisplatin)
CheckMate -9LA: Nivo/ipi + chemo vs chemo
mOS: 14.1 vs 10.7 mo
Durvalumab + tremelimumab + chemotherapy (carboplatin + nab-paclitaxel)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
Durvalumab + tremelimumab + chemotherapy (pemetrexed + carboplatin/cisplatin)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
IMMUNOTHERAPY MONOTHERAPY
Pembrolizumab
KEYNOTE-042: Pembro vs plat-based chemo
mOS: 16.7 vs 12.1 mo (HR, 0.81)
DUAL IMMUNOTHERAPY
Nivolumab + ipilimumab
CheckMate -227: Nivo/ipi vs chemo
mOS: 17.1 vs 14.9 mo
DUAL IMMUNOTHERAPY + CHEMOTHERAPY
Nivolumab + ipilimumab + chemotherapy (pemetrexed + carboplatin/cisplatin)
CheckMate -9LA: Nivo/ipi + chemo vs chemo
OS: 14.1 vs 10.7 mo
Durvalumab + tremelimumab + chemotherapy (carboplatin + nab-paclitaxel)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
Durvalumab + tremelimumab + chemotherapy (pemetrexed + carboplatin/
cisplatin)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
PD- L1 1%- 49%
IMMUNOTHERAPY + CHEMOTHERAPY
SQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin + paclitaxel/nab-paclitaxel)
KEYNOTE-407: Pembro + chemo vs chemo
mPFS: 6.4 vs 4.8 mo (HR, 0.56); mOS: 15.9 vs 11.3 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(paclitaxel + carboplatin/cisplatin)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
NONSQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin + pemetrexed)
KEYNOTE-189: Pembro + chemo vs chemo
mPFS: 8.8 vs 4.9 mo (HR, 0.52); 12-mo OS: 69% vs 49% (HR, 0.49)
• Atezolizumab + chemotherapy (carboplatin + paclitaxel + bevacizumab)
IMpower150: Atezo + chemo vs chemo
mPFS: 8.3 vs 6.8 mo (HR, 0.62)
• Atezolizumab + chemotherapy (carboplatin + albumin-bound paclitaxel)
IMpower130: Atezo + chemo vs chemo
mOS: 18.6 vs 13.9 mo (HR, 0.79); mPFS: 7.0 vs 5.5 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
PD-L1 ≥50%
IMMUNOTHERAPY MONOTHERAPY
Pembrolizumab
a
KEYNOTE-024: Pembro vs platinum-based chemo
mPFS: 10.3 vs 6 mo (HR, 0.50)
Atezolizumab
a
I M p ower 110: Atezo vs platinum-based chemo
mOS: 20.1 vs 13.1 mo (HR, 0.59)
Cemiplimab
a
EMPOWER-Lung1: Cemi vs platinum-based chemo
mPFS: 8.2 vs 5.7 mo; mOS: NR vs 14.2 mo (HR, 0.57)
IMMUNOTHERAPY + CHEMOTHERAPY
SQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin + paclitaxel/nab-paclitaxel)
KEYNOTE-407: Pembro + chemo vs chemo
mPFS: 6.4 vs 4.8 mo (HR, 0.56); mOS: 15.9 vs 11.3 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(paclitaxel + carboplatin/cisplatin)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
NONSQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
KEYNOTE-189: Pembro + chemo vs chemo
mPFS: 8.8 vs 4.9 mo (HR, 0.52); 12-mo OS: 69% vs 49% (HR, 0.49)
• Atezolizumab + chemotherapy (carboplatin + paclitaxel + bevacizumab)
IMpower150: Atezo + chemo vs chemo
mPFS: 8.3 vs 6.8 mo (HR, 0.62)
• Atezolizumab + chemotherapy (carboplatin + albumin-bound paclitaxel)
IMpower130: Atezo + chemo vs chemo
mOS: 18.6 vs 13.9 mo (HR, 0.79); mPFS: 7.0 vs 5.5 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
• Cemiplimab + chemotherapy (paclitaxel + carboplatin or cisplatin)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
No actionable mutation detected (stratify based on PD-L1 staining %)
NSCLC Treatment Algorithm
1
Full abbreviations, accreditation, and disclosure information available at PeerView.com/TFK40
Denotes NCCN-preferred regimens.
b
For patients who have no contraindications to PD-1 or PD-L1 inhibitors and who have a PS 0-1.
1. Adapted from an algorithm created by Aakash Desai, MBBS, MPH, and Matthew Ho, MD, PhD, with recent updates from NCCN Guidelines Version 5, 2024. Used with permission from the authors.
PD- L1 <1%
b
IMMUNOTHERAPY + CHEMOTHERAPY
SQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin + paclitaxel/nab-paclitaxel)
KEYNOTE-407: Pembro + chemo vs chemo
mPFS: 6.4 vs 4.8 mo (HR, 0.56); mOS: 15.9 vs 11.3 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(paclitaxel + carboplatin/cisplatin)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
NONSQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
KEYNOTE-189: Pembro + chemo vs chemo
mPFS: 8.8 vs 4.9 mo (HR, 0.52); 12-mo OS: 69% vs 49% (HR, 0.49)
• Atezolizumab + chemotherapy (carboplatin + paclitaxel + bevacizumab)
IMpower150: Atezo + chemo vs chemo
mPFS: 8.3 vs 6.8 mo (HR, 0.62)
• Atezolizumab + chemotherapy (carboplatin + nab-paclitaxel)
IMpower130: Atezo + chemo vs chemo
mOS: 18.6 vs 13.9 mo (HR, 0.79); mPFS: 7.0 vs 5.5 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
DUAL IMMUNOTHERAPY + CHEMOTHERAPY
SQUAMOUS:
• Nivolumab + ipilimumab + chemotherapy (paclitaxel/carboplatin)
CheckMate -9LA: Nivo/ipi + chemo vs chemo
mOS: 14.1 vs 10.7 mo
• Durvalumab + tremelimumab + chemotherapy (carboplatin + nab-paclitaxel)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
• Durvalumab + tremelimumab + chemotherapy (gemcitabine + carboplatin/cisplatin)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
NONSQUAMOUS:
• Nivolumab + ipilimumab + chemotherapy (paclitaxel/carboplatin)
CheckMate -9LA: Nivo/ipi + chemo vs chemo
mOS: 14.1 vs 10.7 mo
• Durvalumab + tremelimumab + chemotherapy (carboplatin + nab - paclitaxel)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
• Durvalumab + tremelimumab + chemotherapy (pemetrexed + carboplatin/cisplatin)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
DUAL IMMUNOTHERAPY
Nivolumab + ipilimumab
CheckMate -227: Nivo/ipi vs chemo
mOS: 17.1 vs 14.9 mo
DUAL IMMUNOTHERAPY
Nivolumab + ipilimumab
CheckMate -227: Nivo/ipi vs chemo
mOS: 17.1 vs 14.9 mo
DUAL IMMUNOTHERAPY + CHEMOTHERAPY
Nivolumab + ipilimumab + chemotherapy (pemetrexed + carboplatin/cisplatin)
CheckMate -9LA: Nivo/ipi + chemo vs chemo
mOS: 14.1 vs 10.7 mo
Durvalumab + tremelimumab + chemotherapy (carboplatin + nab-paclitaxel)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
Durvalumab + tremelimumab + chemotherapy (pemetrexed + carboplatin/cisplatin)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
IMMUNOTHERAPY MONOTHERAPY
Pembrolizumab
KEYNOTE-042: Pembro vs plat-based chemo
mOS: 16.7 vs 12.1 mo (HR, 0.81)
DUAL IMMUNOTHERAPY
Nivolumab + ipilimumab
CheckMate -227: Nivo/ipi vs chemo
mOS: 17.1 vs 14.9 mo
DUAL IMMUNOTHERAPY + CHEMOTHERAPY
Nivolumab + ipilimumab + chemotherapy (pemetrexed + carboplatin/cisplatin)
CheckMate -9LA: Nivo/ipi + chemo vs chemo
OS: 14.1 vs 10.7 mo
Durvalumab + tremelimumab + chemotherapy (carboplatin + nab-paclitaxel)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
Durvalumab + tremelimumab + chemotherapy (pemetrexed + carboplatin/
cisplatin)
POSEIDON: Durva/treme + chemo vs chemo (see FDA approval)
mOS: 13.3 vs 11.7 mo (HR, 0.86)
PD- L1 1%- 49%
IMMUNOTHERAPY + CHEMOTHERAPY
SQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin + paclitaxel/nab-paclitaxel)
KEYNOTE-407: Pembro + chemo vs chemo
mPFS: 6.4 vs 4.8 mo (HR, 0.56); mOS: 15.9 vs 11.3 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(paclitaxel + carboplatin/cisplatin)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
NONSQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin + pemetrexed)
KEYNOTE-189: Pembro + chemo vs chemo
mPFS: 8.8 vs 4.9 mo (HR, 0.52); 12-mo OS: 69% vs 49% (HR, 0.49)
• Atezolizumab + chemotherapy (carboplatin + paclitaxel + bevacizumab)
IMpower150: Atezo + chemo vs chemo
mPFS: 8.3 vs 6.8 mo (HR, 0.62)
• Atezolizumab + chemotherapy (carboplatin + albumin-bound paclitaxel)
IMpower130: Atezo + chemo vs chemo
mOS: 18.6 vs 13.9 mo (HR, 0.79); mPFS: 7.0 vs 5.5 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
PD-L1 ≥50%
IMMUNOTHERAPY MONOTHERAPY
Pembrolizumab
a
KEYNOTE-024: Pembro vs platinum-based chemo
mPFS: 10.3 vs 6 mo (HR, 0.50)
Atezolizumab
a
I M p ower 110: Atezo vs platinum-based chemo
mOS: 20.1 vs 13.1 mo (HR, 0.59)
Cemiplimab
a
EMPOWER-Lung1: Cemi vs platinum-based chemo
mPFS: 8.2 vs 5.7 mo; mOS: NR vs 14.2 mo (HR, 0.57)
IMMUNOTHERAPY + CHEMOTHERAPY
SQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin + paclitaxel/nab-paclitaxel)
KEYNOTE-407: Pembro + chemo vs chemo
mPFS: 6.4 vs 4.8 mo (HR, 0.56); mOS: 15.9 vs 11.3 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(paclitaxel + carboplatin/cisplatin)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
NONSQUAMOUS:
• Pembrolizumab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
KEYNOTE-189: Pembro + chemo vs chemo
mPFS: 8.8 vs 4.9 mo (HR, 0.52); 12-mo OS: 69% vs 49% (HR, 0.49)
• Atezolizumab + chemotherapy (carboplatin + paclitaxel + bevacizumab)
IMpower150: Atezo + chemo vs chemo
mPFS: 8.3 vs 6.8 mo (HR, 0.62)
• Atezolizumab + chemotherapy (carboplatin + albumin-bound paclitaxel)
IMpower130: Atezo + chemo vs chemo
mOS: 18.6 vs 13.9 mo (HR, 0.79); mPFS: 7.0 vs 5.5 mo (HR, 0.64)
• Cemiplimab + chemotherapy
a
(carboplatin/cisplatin + pemetrexed)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
• Cemiplimab + chemotherapy (paclitaxel + carboplatin or cisplatin)
EMPOWER-Lung 3: Cemi + chemo vs chemo (see FDA approval)
mOS: 21.9 vs 13 mo (HR, 0.7)
No actionable mutation detected (stratify based on PD-L1 staining %)
NSCLC Treatment Algorithm
1
Full abbreviations, accreditation, and disclosure information available at PeerView.com/TFK40
lungevity.org
• Patients and providers joined forces to make a discussion tool that helps
patients understand how their biomarker test results influence choosing the right
treatment for their solid-tumor cancer
• This discussion guide can support people with solid-tumor cancer to ask
their doctor or nurse the right questions about biomarker testing, ensure they
received the optimal level of biomarker testing, and understand how biomarker
testing can expand their optimal treatment options, including clinical trials
• The guide can also be used by healthcare providers to teach their patients
about how biomarker test results are used to make decisions about optimal
treatment and clinical trial options
LUNGevity offers a simplified guide to biomarker testing discussions for
patients and their healthcare team. It is available for download and can
be personalized with your institution’s logo and contact details.
The next page includes a tool designed for people with solid-tumor
cancer to use in communication about biomarker results
with their healthcare providers LUNGevity Foundation
Biomarker Testing Discussion Guide for Patients
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/TFK40
• Patients and providers joined forces to make a discussion tool that helps
patients understand how their biomarker test results influence choosing the right
treatment for their solid-tumor cancer
• This discussion guide can support people with solid-tumor cancer to ask
their doctor or nurse the right questions about biomarker testing, ensure they
received the optimal level of biomarker testing, and understand how biomarker
testing can expand their optimal treatment options, including clinical trials
• The guide can also be used by healthcare providers to teach their patients
about how biomarker test results are used to make decisions about optimal
treatment and clinical trial options
LUNGevity offers a simplified guide to biomarker testing discussions for
patients and their healthcare team. It is available for download and can
be personalized with your institution’s logo and contact details.
The next page includes a tool designed for people with solid-tumor
cancer to use in communication about biomarker results
with their healthcare providers LUNGevity Foundation
Biomarker Testing Discussion Guide for Patients
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/TFK40
Understanding Your Lung Cancer
Can Lead to Better Treatment Options
1. Has the cancer been tested for all biomarkers?
2. When is a tissue biomarker test necessary?
3. When is a blood biomarker test (ie, liquid biopsy) necessary?
4. How can I get a copy of my biomarker testing report?
5. Who will explain my biomarker testing results to me?
6. Is cancer biomarker testing the same as genetic testing for inherited cancer?
Are my family/children at risk?
7. Will I ever have to have more biomarker testing?
This tool is designed for people with solid-tumor cancer to use in communication
about biomarker results with their healthcare providers.
Was my tumor tested for biomarkers?
a
Did my test results show any biomarkers?
Let’s discuss your options
Based on my biomarker
results, how do we
decide what is the best
treatment for me?
Based on my
results, how
do we
decide if a
treatment
or clinical
trial is right
for me?
Would
more tests
offer more
treatment
options?
Let’s
discuss
the
approved
and
available
treatment
options
Let’s
discuss
other
potential
treatments
(ie, clinical
trials)
Can you get more tissue?
Let’s discuss
your options
What
resources
are
available
to help
pay for
the
costs?
NO
NO
Tissue
Will I need
another
biopsy?
We could test
tissue and/or
your blood
Blood
How long until I get
the results from the
repeat testing?
Could I get a
blood test
(liquid biopsy)?
Yes, there are biomarkers
we can use to make a
treatment plan
Yes, but none that we can
use to make a treatment
plan at this time
Has my cancer been tested
for all treatable biomarkers
and biomarkers for
clinical trials?
NO Why?
NO NO
No, because there was not
enough tissue for testing
No
biomarkers
NO
Will my insurance
cover the testing?
Trusting your core team
and treatment plan is
important. Seeking a
second opinion may
increase your trust in
your care plan.
lungevity.org
Suggested
Questions
to Ask
Your Team
YES
YES
YESYES
YES
a
Biomarkers are changes in the cancer cells that may help guide treatment. Most biomarkers used to guide treatment plans are not passed on to children/family.
Developed by LUNGevity Foundation in partnership with clinical experts and patients with cancer.
Can Lead to Better Treatment Options
1. Has the cancer been tested for all biomarkers?
2. When is a tissue biomarker test necessary?
3. When is a blood biomarker test (ie, liquid biopsy) necessary?
4. How can I get a copy of my biomarker testing report?
5. Who will explain my biomarker testing results to me?
6. Is cancer biomarker testing the same as genetic testing for inherited cancer?
Are my family/children at risk?
7. Will I ever have to have more biomarker testing?
This tool is designed for people with solid-tumor cancer to use in communication
about biomarker results with their healthcare providers.
Was my tumor tested for biomarkers?
a
Did my test results show any biomarkers?
Let’s discuss your options
Based on my biomarker
results, how do we
decide what is the best
treatment for me?
Based on my
results, how
do we
decide if a
treatment
or clinical
trial is right
for me?
Would
more tests
offer more
treatment
options?
Let’s
discuss
the
approved
and
available
treatment
options
Let’s
discuss
other
potential
treatments
(ie, clinical
trials)
Can you get more tissue?
Let’s discuss
your options
What
resources
are
available
to help
pay for
the
costs?
NO
NO
Tissue
Will I need
another
biopsy?
We could test
tissue and/or
your blood
Blood
How long until I get
the results from the
repeat testing?
Could I get a
blood test
(liquid biopsy)?
Yes, there are biomarkers
we can use to make a
treatment plan
Yes, but none that we can
use to make a treatment
plan at this time
Has my cancer been tested
for all treatable biomarkers
and biomarkers for
clinical trials?
NO Why?
NO NO
No, because there was not
enough tissue for testing
No
biomarkers
NO
Will my insurance
cover the testing?
Trusting your core team
and treatment plan is
important. Seeking a
second opinion may
increase your trust in
your care plan.
lungevity.org
Suggested
Questions
to Ask
Your Team
YES
YES
YESYES
YES
a
Biomarkers are changes in the cancer cells that may help guide treatment. Most biomarkers used to guide treatment plans are not passed on to children/family.
Developed by LUNGevity Foundation in partnership with clinical experts and patients with cancer.
LUNGevity Foundation
Lung Cancer Patient Resource Compendium
Full abbreviations, accreditation, and disclosure information available at PeerView.com/TFK40
LUNGevity is transforming how people are diagnosed and live
with lung cancer through research, education, and support
LUNGevity educational materials order form for providers:
www.lungevity.org/order-materials
The next page includes useful links to resources for patients with lung cancer
lungevity.org
Lung Cancer Patient Resource Compendium
Full abbreviations, accreditation, and disclosure information available at PeerView.com/TFK40
LUNGevity is transforming how people are diagnosed and live
with lung cancer through research, education, and support
LUNGevity educational materials order form for providers:
www.lungevity.org/order-materials
The next page includes useful links to resources for patients with lung cancer
lungevity.org
lungevity.org
• The Lung Cancer 101 Website
provides a guide to understanding
the basics of lung cancer
• The Lung Cancer Support
Community message boards offer
24/7 peer-to-peer support and
information
• The LifeLine Program matches
patients and caregivers to mentors
LUNGevity offers the largest online network of peer-to-peer and one-on-one support,
plus in-person survivorship programs for all people affected by lung cancer
LUNGevity hosts weekly lung cancer support Virtual Meetups
for patients, survivors, caregivers, and friends and family members of people
with lung cancer to virtually connect face-to-face with others across the country
Please call 312-407-6116 for more information
• The Lung Cancer HELPLine
offers toll-free, personalized
support in English and Spanish
• Patient Gateways help navigate
specific types of lung cancer
• LUNGevity’s Hope Summit is
designed to inform, connect, and
empower anyone who has been
affected by lung cancer
• The Lung Cancer 101 Website
provides a guide to understanding
the basics of lung cancer
• The Lung Cancer Support
Community message boards offer
24/7 peer-to-peer support and
information
• The LifeLine Program matches
patients and caregivers to mentors
LUNGevity offers the largest online network of peer-to-peer and one-on-one support,
plus in-person survivorship programs for all people affected by lung cancer
LUNGevity hosts weekly lung cancer support Virtual Meetups
for patients, survivors, caregivers, and friends and family members of people
with lung cancer to virtually connect face-to-face with others across the country
Please call 312-407-6116 for more information
• The Lung Cancer HELPLine
offers toll-free, personalized
support in English and Spanish
• Patient Gateways help navigate
specific types of lung cancer
• LUNGevity’s Hope Summit is
designed to inform, connect, and
empower anyone who has been
affected by lung cancer
Categories
EducationDownload
Download Slideshow Get the original presentation fileQuick Actions
Statistics
- Views 290
- Slides 7
- Age 518 days
Related Slideshows
11
TLE-9-Prepare-Salad-and-Dressing.pptxkkk
MaAngelicaCanceran
32 views
12
LESSON 1 ABOUT MEDIA AND INFORMATION.pptx
JojitGueta
24 views
60
GRADE-8-AQUACULTURE-WEEKQ1.pdfdfawgwyrsewru
MaAngelicaCanceran
40 views
26
Feelings PP Game FOR CHILDREN IN ELEMENTARY SCHOOL.pptx
KaistaGlow
39 views
![Jeopardy_Figures_of_Speech_Template.pptx [Autosaved].pptx](https://slidepub.com/thumb/5828/284015828.jpg)
54
Jeopardy_Figures_of_Speech_Template.pptx [Autosaved].pptx
acecamero20
23 views
7
Jeopardy_Figures_of_Speech.pptxvdsvdsvsdvsd
acecamero20
24 views